EQUITY PURCHASE AGREEMENTEquity Purchase Agreement • July 20th, 2020 • Nugenerex Immuno-Oncology, Inc. • Pharmaceutical preparations • New York
THIS EQUITY PURCHASE AGREEMENT (this “Agreement”) is entered into as of July 14, 2020 (the “Execution Date”), by and between NuGenerex Immuno-Oncology Inc., a Delaware corporation (the “Company”), and Oasis Capital, LLC, a Puerto Rico limited liability company (the “Investor”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 20th, 2020 • Nugenerex Immuno-Oncology, Inc. • Pharmaceutical preparations • New York
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July 14, 2020 (the “Execution Date”), is entered into by and between NUGENEREX IMMUNO-ONCOLOGY INC., a Delaware corporation (the “Company”), and OASIS CAPITAL, LLC, a Puerto Rico limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in that certain Equity Purchase Agreement by and between the parties hereto, dated as of the Execution Date (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
Framework Agreement on Cooperative Development of Coronavirus Peptide VaccineFramework Agreement • November 5th, 2020 • Nugenerex Immuno-Oncology, Inc. • Pharmaceutical preparations
Party C: Chinese Centre for Disease Control and Prevention National Institute for Viral Disease Control and Prevention(NIVDC)
LICENSE AND RESEARCH AGREEMENT BETWEEN ANTIGEN EXPRESS, INC. (A WHOLLY-OWNED SUBSIDIARY OF GENEREX BIOTECHNOLOGY CORPORATION) AND SHENZHEN BIOSCIEN PHARMACEUTICALS CO. LTD. November 29th, 2017License and Research Agreement • July 23rd, 2020 • Nugenerex Immuno-Oncology, Inc. • Pharmaceutical preparations • New York
This License and Research Agreement (the "Agreement"), effective as of the day of November, 2017 (the "Effective Date"), is by and between Antigen Express, Inc., a wholly-owned subsidiary of Generex Biotechnology Corporation, a Delaware corporation, with an address of 4145 North Service Road, Suite 200, Burlington, Ontario, Canada L7L 6A3 (hereinafter referred as "Licensor"), and Shenzhen BioScien Pharmaceuticals Co., Ltd., located at Room 311, First Building, Shenzhen Overseas Venture Park (Longgang), Shenzhen 518116, Guangdong, China (hereinafter referred to as "Licensee"). Licensor and Licensee may each be referred to herein individually as a "Party" and collectively
CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENTClinical Trial Collaboration and Supply Agreement • June 12th, 2020 • Nugenerex Immuno-Oncology, Inc. • Pharmaceutical preparations • New York
Contract No.: YF202011-A Contract Date: 13th-Nov-2020Vaccine Development Agreement • November 18th, 2020 • Nugenerex Immuno-Oncology, Inc. • Pharmaceutical preparations
Explanation of Ii-key technology: technical mechanism, technical logic, application scenarios, intellectual property list, published literature lists, showcases of the technology and list of out licensed deals.
Clinical Trial AgreementClinical Trial Agreement • June 12th, 2020 • Nugenerex Immuno-Oncology, Inc. • Pharmaceutical preparations • Pennsylvania
This Clinical Trial Agreement (“Agreement”) is entered into and effective as of the 20th day of November, 2018 (“Effective Date”), by and between NSABP Foundation, Inc., a 501(c)(3) non-profit Pennsylvania membership corporation with its principal office and place of business at Nova Tower 2, Two Allegheny Center, Suite 1200, Pittsburgh, Pennsylvania 15212-5234 (“NSABP”), and Antigen Express, Inc., a Delaware corporation with its principal office and place of business at 33 Redwing Road, Wellesley, MA 02481 (“Antigen Express”). NSABP and Antigen Express shall hereinafter be referred to individually as “Party,” and together as “Parties.”
DATED THIS DAY OF 05 OCT 2020 BETWEEN GENEREX BIOTECHNOLOGY CORPORATION ("GENEREX") AND NUGENEREX IMMUNO-ONCOLOGY, INC. (''NUGENEREX") AND BINTAI HEALTHCARE SDN BHD ("BHSB") DISTRIBUTION AND LICENSING AGREEMENTDistribution and Licensing Agreement • October 14th, 2020 • Nugenerex Immuno-Oncology, Inc. • Pharmaceutical preparations
NuGenerex Immuno-Oncology, Inc. a majority owned subsidiary of Generex Biotechnology Corporation, each a Delaware corporation with an office address of 10102 USA Today Way, Miramar, FL 33025 ("NuGenerex")
DATED THIS 21st DAY OF November 2020 BETWEEN BINTAI HEALTHCARE SDN. BHD. (Company Registration No. 1384306-P) AND GENEREX BIOTECHNOLOGY CORPORATION & NUGENEREX IMMUNO-ONCOLOGY, INC MEMORANDUM OF UNDERSTANDING MEMORANDUM OF UNDERSTANDINGMemorandum of Understanding • November 25th, 2020 • Nugenerex Immuno-Oncology, Inc. • Pharmaceutical preparations
Bintai Kinden Corporation Berhad (a public listed company in Malaysia listed on Bursa Malaysia) and incorporated in Malaysia under the Companies Act 2016 and having its business address at 3-2-8 Kompleks Kantonmen Prima, No. 698, Jalan Ipoh, 51200 Kuala Lumpur, Malaysia (“Bintai”).
FORBEARANCE AGREEMENTForbearance Agreement • July 23rd, 2020 • Nugenerex Immuno-Oncology, Inc. • Pharmaceutical preparations • Maryland
This FORBEARANCE AGREEMENT (this "Agreement"), effective as of the last date of signature below (hereinafter the "Effective Date"), is entered into by and among Antigen Express, Inc. ("Antigen Express") and Generex Biotechnology Corporation ("Generex," and together with Antigen Express the "Companies") and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (the "Foundation"). The Companies and Foundation sometimes are referred to collectively as the "Parties" or individually as a "Party."
